Agomab Therapeutics NV

Pre-IPO, Agomab raised €299.7 million total from named strategic and institutional investors

Named investors in 424B4: Andera Partners, Boehringer Ingelheim Venture Fund, Canaan, Cormorant Asset Management, Dawn Biopharma (KKR platform), EQT Life Sciences, Fidelity Management & Research Company, Invus, Pfizer, Pontifax, Redmile, and Sanofi. Outstanding preferred shares (converted at IPO) = 33,626,042 common shares.

FMR LLC (Fidelity) holds 4,873,680 shares = exactly 10.0% of Agomab post-IPO, as disclosed in Schedule 13G filed March 6, 2026

Holdings as of February 27, 2026. Filed as a non-U.S. institution. Abigail P. Johnson also a reporting person. CIK 0000315066. FMR LLC was named as a pre-IPO investor (Fidelity Management & Research Company) in the 424B4.

AGMB trading at $10.85 as of 2026-03-29, down 32% from IPO price; market cap ~$534M, enterprise value ~$130M implying ~$400M net cash

52-week range $10.51–$17.45. Price on observation date near 52-week low. Significant premium of market cap over enterprise value suggests large cash balance consistent with $181M net IPO proceeds plus pre-existing cash from €299.7M pre-IPO raises.

Agomab Therapeutics NV incorporated in Belgium on April 13, 2017 as BVBA; converted to NV on March 14, 2019

Per 424B4: 'We were initially incorporated under the laws of Belgium on April 13, 2017 as a Belgian private limited liability company (besloten vennootschap) and were converted under the laws of Belgium into a Belgian limited liability company (naamloze vennootschap) on March 14, 2019.' Belgian registration number 0674527310. GLEIF LEI 894500APP6UE5N4PKJ68.

Agomab filed a confidential Draft Registration Statement (DRS) with SEC on June 20, 2024 — 19 months before the final F-1 was made public

DRS filed 2024-06-20 (CIK 0002020932). Two DRS/A amendments followed: 2025-10-28 and 2025-12-17. F-1 made public 2026-01-16, F-1/A 2026-01-29, EFFECT 2026-01-30. This indicates the company began formal SEC preparation approximately 20 months before IPO, consistent with a thorough preparation process.

Agomab Therapeutics NV completed Nasdaq IPO on February 9, 2026 at $16.00/ADS, raising $200M gross ($181M net)

12,500,000 ADSs were sold at $16.00 per ADS. Underwriters: J.P. Morgan, Morgan Stanley, Leerink Partners, Van Lanschot Kempen. Each ADS represents one common share. 48,736,779 shares outstanding post-IPO. Source: 424B4 filed 2026-02-06.

argenx BV received 2,069,611 common shares upon conversion of a 'profit sharing certificate' at IPO closing

Per 424B4: 'the issuance of 2,069,611 common shares to argenx BV upon the conversion of argenx BV's profit sharing certificate, or the profit sharing certificate, immediately prior to the consummation of this offering.' This represents approximately 4.2% of post-IPO shares outstanding. The nature of the underlying arrangement giving rise to the profit sharing certificate is not described in the 424B4 text reviewed.

Boehringer Ingelheim Venture Fund invested in Agomab while Boehringer Ingelheim parent competes directly in IPF with Ofev (nintedanib) and Jascayd (nerandomilast)

424B4 names Boehringer Ingelheim Venture Fund as a pre-IPO investor. The same document identifies three FDA-approved IPF therapies: pirfenidone (Roche), nintedanib/Ofev (Boehringer Ingelheim), and nerandomilast/Jascayd (Boehringer Ingelheim). Agomab's AGMB-447 targets the same IPF indication. This dual investor-competitor relationship creates structural tension and potential information asymmetry risk.

LSP 7 Cooperatieve U.A. (Amsterdam) filed Schedule 13D disclosing pre-IPO preferred share purchases of approximately 185,585 shares and an Amended and Restated Shareholders' Agreement

LSP is a European life sciences VC (Life Sciences Partners). Fund vehicle: LSP 7 Cooperatieve U.A., managed by LSP 7 Management B.V. MDs: Martijn Kleijwegt, Rene Kuijten. Reporting person: Bas Vaessen. Address: Johannes Vermeerplein 9, 1071 DV Amsterdam. Filed 8 days after IPO, within 10-day 13D deadline.

S-8 registered 10 equity compensation plans covering option grants from 2019 through 2026

Plans: ESOP March 2019, ESOP September 2019, ESOP March 2020, ESOP October 2020, Global Stock Option Plan March 2021, 2022/2023/2024/2024(B)/2026 Global Stock Option Plans. Outside counsel: Michael H. Bison and Roel Meers (likely Goodwin Procter and Belgian counsel respectively).

All 11 Section 16 insiders filed Form 3 (initial ownership statements) on 2026-03-18, approximately 37 days after IPO close on Feb 9, 2026

Insiders: Tim Knotnerus (Director+CEO), Ellen Lefever (GC), Andrea Saez Borderias (CDO), Paul Van Der Horst (CBO), Philippe Wiesel (CMO), Pierre Kemula (CFO), Colin Bond (Dir), David Epstein (Dir), Ohad Hammer (Dir), Angelika Jahreis (Dir), Felice Verduyn-Van Weegen (Dir). All report Posthoflei 1/6 Antwerpen. All Form 3 Table I show no non-derivative securities (warrants only). Note: Agomab is an FPI exempt from Section 16 short-swing rules; Form 3 filings appear voluntary.

Agomab announced Phase 2a STENOVA trial topline results in November 2025; primary endpoint (safety/tolerability) achieved; GI-restricted PK profile confirmed; positive signals on exploratory endpoints

STENOVA was a global randomized double-blind placebo-controlled Phase 2a trial in 103 FSCD symptomatic patients. Ontunisertib 100mg QD and 200mg BID. 48-week open-label extension ongoing; results expected H2 2026. Phase 2b planned H2 2026. FDA Fast Track Designation received 2023.